Cmic CRO Of Japan To Buy Drug-Production Plant From Daiichi Sankyo
This article was originally published in PharmAsia News
Executive Summary
Japan's Cmic plans to buy a Daiichi Sankyo manufacturing plant to produce oral and injection drug formulations. The contract research organization is expanding its business beyond conducting clinical trials to producing products for pharmaceutical companies, including Daiichi Sankyo. The acquisition of the Daiichi Sankyo Propharma plant in Japan is expected to give Cmic the capacity to produce 1.5 billion tablets and 3 million vials of drugs a year. The purchase price still has to be settled between the two firms. (Click here for more - a subscription may be required